RabMAb

Anti-p53 (acetyl K382)抗体[EPR358(2)] (ab75754)

发表研究结果有使用 ab75754?请让我们知道,以便我们可以引用本数据表中的参考文章。

ab75754 被引用在 8 文献中.

  • Kim TH  et al. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts. Biochim Biophys Acta 1850:401-10 (2015). PubMed: 25445714
  • Allison SJ  et al. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. Oncogenesis 3:e102 (2014). WB ; Human . PubMed: 24819061
  • Ming M  et al. SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33 (2014). PubMed: 25320180
  • van Leeuwen IM  et al. Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2. Mol Cancer Ther 12:471-80 (2013). Human . PubMed: 23416275
  • Savaryn JP  et al. Human cytomegalovirus pUL29/28 and pUL38 repression of p53-regulated p21CIP1 and caspase 1 promoters during infection. J Virol 87:2463-74 (2013). PubMed: 23236067
  • Knight JR  et al. Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity. Open Biol 3:130130 (2013). WB . PubMed: 24258275
  • Warnock LJ  et al. Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53. Cancer Biol Ther 12: (2011). WB . PubMed: 22157150
  • Guo X  et al. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem 285:13223-32 (2010). WB ; Human . PubMed: 20167603

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"